In focus · trending topic

Lebers congenital amaurosis

18 stories · following the connections

ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO

By Nasdaq OMXApr 23, 2018, 11:00 AM UTC

ProQR to Present at the Annual Piper Jaffray Healthcare Conference

By Nasdaq OMXNov 21, 2017, 12:00 PM UTC

ProQR Announces Results for the Second Quarter of 2017

By Nasdaq OMXAug 16, 2017, 11:00 AM UTC

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC